Harvard Bioscience/$HBIO
1D1W1MYTD1Y5YMAX
Capital at risk
About Harvard Bioscience
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
- Ticker
- $HBIO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 328
- Headquarters
- Holliston, United States
- Website
- www.harvardbioscience.com
HBIO Metrics
BasicAdvanced
$37M
-
-$2.35
1.49
-
Price and volume
Market cap
$37M
Beta
1.49
52-week high
$8.40
52-week low
$4.27
Average daily volume
21K
Financial strength
Current ratio
1.874
Quick ratio
0.847
Long term debt to equity
5.744
Total debt to equity
5.959
Interest coverage (TTM)
0.30%
Profitability
EBITDA (TTM)
7.37
Gross margin (TTM)
58.16%
Net profit margin (TTM)
-11.86%
Operating margin (TTM)
2.24%
Effective tax rate (TTM)
1.22%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
1.58%
Return on equity (TTM)
-89.95%
Valuation
Price to revenue (TTM)
0.409
Price to book
4.93
Price to tangible book (TTM)
-4.5
Price to free cash flow (TTM)
-19.598
Free cash flow yield (TTM)
-5.10%
Free cash flow per share (TTM)
-0.41
Growth
Revenue change (TTM)
-1.06%
Earnings per share change (TTM)
-82.03%
3-year revenue growth (CAGR)
-8.36%
10-year revenue growth (CAGR)
-1.98%
3-year earnings per share growth (CAGR)
21.91%
10-year earnings per share growth (CAGR)
-8.55%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.